Sign Out
In clinical studies with PROPECIA in men 18-41 years of age, the mean value of serum prostate-specific antigen (PSA) decreased from 0.7 ng/mL at baseline to 0.5 ng/mL at Month 12. When PROPECIA is used for treatment of male pattern hair loss in older men who also have benign prostatic hyperplasia (BPH), consideration should be given to the fact that, in older men with BPH, PSA levels are decreased by approximately 50%.
Use in Children: PROPECIA is not indicated for use in children.
Use in the Elderly: Clinical studies with PROPECIA have not been conducted in elderly men with male pattern hair loss.
